GlassScriptPhysician profile
Monal Patel
NPI 1245841451
$6,557.52
in general payments reported to CMS, 2019-2025
19 companies · $2,761 in 2025
The $2,761 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,054 · 2023: $1,475 · 2024: $1,269 · 2025: $2,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,305 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,304.84 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,096.89 | 2022-2025 | |
| Amgen INC. | $1,271.21 | 2022-2025 | Enbrel, Otezla, Krystexxa |
| Janssen Biotech, INC. | $841.13 | 2022-2025 | Tremfya, Stelara, Remicade |
| Novartis Pharmaceuticals Corporation | $831.09 | 2022-2025 | |
| Ucb, INC. | $424.48 | 2023-2025 | Bimzelx, Cimzia |
| Mallinckrodt Hospital Products INC. | $193.64 | 2022-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.97 | 2022-2025 | Ofev |
| Bioventus LLC | $149.13 | 2025 | Gelsyn-3 |
| E.R. Squibb & Sons, L.L.C. | $112.48 | 2024-2025 | Orencia |
| Radius Health, INC. | $92.27 | 2023-2024 | Tymlos |
| Ani Pharmaceuticals, INC. | $89.79 | 2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $65.02 | 2023-2025 | Saphnelo |
| Sobi, INC | $43.59 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $36.27 | 2023-2025 | Strensiq |
| Lilly USA, LLC | $35.89 | 2023-2024 | Taltz |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $22.29 | 2023 | Opsumit, Uptravi |
| Pfizer INC. | $22.09 | 2025 | |
| Glaxosmithkline, LLC. | $19.49 | 2025 | Benlysta |
| Organon LLC | $18.80 | 2025 | Hadlima, Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.